Owners and insurers agree to a $100M fund for victims of NECC’s tainted drugs

Eric Palmer The fungal meningitis outbreak tied to New England Compounding Center led to the bankruptcy of the company and new authority for the FDA to oversee this niche of the drug ...

J&J innovation team sets up international collaboration to discover Alzheimer’s drugs

John Carroll J&J has spent hundreds of millions of dollars in a so-far failed effort to develop a late-stage biologic that could be used to treat Alzheimer's. And it's now ...

JAMA study raises red flag on big-selling testosterone drugs

Tracy Staton As more and more baby boomers have signed on for testosterone testing–and, in turn, therapy–worries about the safety of testosterone-boosting drugs have ...

Once again, Bayer’s new drugs power pharma sales upward

Carly Helfand Eye drug Eylea and blood thinner Xarelto are pretty good products for any drugmaker to have in its lineup, and Bayer's got them both. Sales of those new stars have ...

U.K. watchdogs push India’s Wockhardt to recall 5 drugs

Tracy Staton U.K. regulators have changed their mind about the need for a Wockhardt recall. The Medicines and Healthcare products Regulatory Agency asked Indian drugmaker Wockhardt to ...

How do U.S. drugs come to cost more? Let us count the ways

Tracy Staton Why the disparity in drug prices? It's a question asked repeatedly, and the specific answers are multifarious and complex.  FiercePharma News

Express Scripts stops covering key Big Pharma drugs on clinical, cost-effectiveness grounds

Tracy Staton A few weeks ago, Novo Nordisk said it had lost Express Scripts' business on two of its top drugs, Victoza and NovoLog. Well, that was just part of the action at the ...

Which new drugs promise to shake up markets the most?

Tracy Staton Every drugmaker dreams of developing a drug so important that it shakes up an entire market. And it happens–just think of Johnson & Johnson's Zytiga, the ...

Drugmakers want to block Maine from cheaper Canadian drugs

Eric Palmer What do you think? Would a buyer rather pay $ 200 for a prescription of AstraZeneca's heartburn medicine Nexium, or $ 620? Seems pretty simple, but that math is at ...

Shutdown nixes Merck’s FDA panel date, spares other drugs

Damian Garde While the plodding government shutdown has thus far left the biotech industry largely unmarred, the furlough-weakened FDA has now postponed an advisory committee hearing, ...

Rival Amgen/AstraZeneca, Novartis drugs race ahead in crowded psoriasis showdown

John Carroll Amgen and its partner AstraZeneca are headed to a scientific conference in Istanbul this weekend to lay out a slate of upbeat mid-stage data on a closely-watched psoriasis ...

Pharmalink grabs $15M VC round for key studies on cancer, renal disease drugs

John Carroll Stockholm-based Pharmalink AB is banking $ 15 million from a C round designed to get one drug through a Phase IIb study and position another therapy for a pivotal trial ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS